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Abstract 25 
Chlamydia trachomatis is an obligate intracellular bacterium that causes severe infections, 26 
which can lead to infertility and ectopic pregnancy. Although both innate and adaptive 27 
immune responses are elicited during chlamydial infection the bacterium succeeds to evade 28 
host defense mechanisms establishing chronic infectons. Thus, studying the host-pathogen 29 
interaction during chlamydial infection is of importance to understand how C. trachomatis 30 
can cause chronic infections. Both the complement system and monocytes play essential roles 31 
in anti-bacterial defense, and, therefore, we investigated the interaction between the 32 
complement system and the human pathogens C. trachomatis D and L2.  33 
 34 
Complement competent serum facilitated rapid uptake of both chlamydial serovars into 35 
monocytes. Using immunoelectron microscopy, we showed that products of complement C3 36 
were loosely deposited on the bacterial surface in complement competent serum and further 37 
characterization demonstrated that the deposited C3 product was the opsonin iC3b. Using C3-38 
depleted serum we confirmed that complement C3 facilitates rapid uptake of chlamydiae into 39 
monocytes in complement competent serum. Complement facili ated uptake did not influence 40 
intracellular survival of C. trachomatis or C. trachomatis-induced cytokine secretion. 41 
Hence, C. trachomatis D and L2 activate the complement system leading to chlamydial 42 
opsonization by iC3b and subsequent phagocytosis, act vation and bacterial elimination by 43 
human monocytes.  44 
 45 
Keywords 46 
monocytes; Chlamydia trachomatis; complement C3 
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1. Introduction 47 
Chlamydia trachomatis is estimated to infect 100 million people annually causing chronic 48 
genital and ocular infections [1]. The course of genital infection is mostly asymptomatic 49 
leaving the infection undiagnosed and untreated. Untreated genital chlamydial infection can 50 
cause severe tissue damage and lead to pelvic inflammatory disease, ectopic pregnancy, and 51 
infertility [2].  52 
C. trachomatis is an obligate intracellular Gram-negative bacterium with a unique biphasic 53 
developmental cycle. The infectious, but metabolic inactive elementary body (EB) infects 54 
epithelial cells in the genital mucosa. Intracellularly, the EB transforms to a larger non-55 
infectious but metabolic active reticulate body (RB) [3].  During entry, C. trachomatis inhibits 56 
phagosome-lysosome fusion and resides in a modified vacuole called an inclusion, which 57 
provides a niche for bacterial replication [4].  58 
Chlamydial infections tend to be chronic even though both humoral and cell-mediated 59 
immunity are elicited [5]. Monocytes and macrophages play essential roles in anti-bacterial 60 
immunity in general, but little is known about the exact role of monocytes during C.61 
trachomatis infections. During infection, epithelial cells respond by secreting several 62 
cytokines and chemokines creating a local inflammatory condition that recruits monocytes to 63 
the site of infection [6]. In vitro studies show tha  several C. trachomatis serovars infect 64 
human monocytes inducing cellular activation with secretion of inflammatory cytokines, such 65 
as IL-1β, IL-6, and IL-8 [7]. Chlamydial uptake into host cells is supposedly carried out by 66 
phagocytosis or by receptor-mediated endocytosis, but the exact mechanisms and the 67 
receptors involved remain elusive [8]. An involvement of plasma membrane lipid rafts and 68 
the mannose receptor have been suggested, but also complement receptors could be involved 69 
since these receptors facilitate uptake of other intracellular bacteria such as Mycobacterium 70 
tuberculosis and Legionella pneumophila [9–12]. 71 
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The complement system consists of more than 30 different proteins comprising both soluble 72 
factors and cell surface receptors [13]. Complement activation initiates a cascade of 73 
proteolytic cleavages leading to both direct and indirect anti-microbial effects. The direct anti-74 
microbicidal functions are carried out by the membrane attack complex (MAC), a pore-75 
formed structure consisting of repetitive membrane-spanning complement factors that causes 76 
membrane permeability and cellular lysis. Another function of the complement system is 77 
mediated by the so-called opsonins, which bind to the surface of pathogens tagging them for 78 
uptake and degradation in professional phagocytes. 79 
The complement system is mainly activated through three distinct pathways which are 80 
triggered by different structural motifs and involve different intermediate complement 81 
products, but they all converge at the common downstream effector C3 convertase. C3 82 
convertase cleaves complement factor C3 into the anaphylatoxin C3a and the opsonin C3b. 83 
C3b may be further cleaved into additional opsonins called iC3b and C3dg. C3b, iC3b, and 84 
C3dg are all recognized by surface receptors expressed on different host immune cells and 85 
opsonin-receptor engagement leads to receptor-mediated phagocytosis of the opsonized 86 
organism. It has been shown that C3b and iC3b are recognized by complement receptor (CR) 87 
1 and CR3, respectively, and both receptors are ubiquitously expressed on monocytes and 88 
macrophages and are important for mononuclear phagocytosis of infectious bacteria [14].  89 
C. trachomatis is able to activate the complement system and it has been demonstrated that C. 90 
trachomatis induced complement activation leads to binding of C3 to the bacterium [15]. 91 
To further explore the interaction between the comple ent system and C. trachomatis, we 92 
investigated how complement deposition on C. trachomatis affects the uptake of chlamydial 93 
EBs into human monocytes and how complement modulates the intracellular fate of C. 94 
trachomatis in monocytes. Uncovering new aspects of the interac ion between complement, 95 
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monocytes, and C. trachomatis are important to understand how chlamydial infections are 96 
controlled by the innate immune system. 97 
 98 
2. Materials and methods 99 
2.1. Antibodies 100 
The following primary antibodies were used in this study: Anti-human CD11b (MEM-174) 101 
(ImmunoTools GmbH, Friesoythe, Germany), Polyclonal R bbit Anti-Human C3c 102 
Complement (Agilent Technologies, Glostrup, Denmark), Mab32.3 against C. trachomatis 103 
MOMP [16], and PAb17 against C. trachomatis outer membrane [17]. FITC-, Alexa Flour® 104 
488-, and rhodamine-conjugated secondary antibodies were purchased from Jackson 105 
ImmunoResarch (Jackson ImmunoResearch, PA, USA). Anti-Rabbit IgG Alkaline 106 
Phosphatase was purchased from Sigma-Aldrich (Sigma-Aldrich, St. Louis, MO, USA). Goat 107 
anti-rabbit antibody conjugated with 10 nm colloidal gold (British BioCell, Cardiff, UK) was 108 
used for immunoelectron microscopy. 109 
 110 
2.2. Bacteria strains and culture 111 
C. trachomatis D/UW-3/cx and L2/434/Bu were obtained from the American Type Culture 112 
Collection (ATCC, VA, USA) and propagated in McCoy cells according to Ripa and Mårdh 113 
[18]. Chlamydia were tested free of mycoplasma by PCR according to Huniche et al. [19]. 114 
McCoy cells were obtained from ATCC and tested freeof mycoplasma by Hoechst 33342 115 
staining and PCR according to[19]. 116 
C. trachomatis D and L2 EB were purified by density gradient centrifugation essentially 117 
according to Caldwell et al. 1981 [20] and purity was estimated using negative staining and 118 
transmission electron microscopy (TEM), (see 2.7) 119 
 120 
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2.3. Cell isolation and culture 121 
Blood samples were obtained from C. trachomatis seronegative donors at Aalborg University 122 
(Approved by The Ethics Committee of Region Nordjylland, case no. N-20150073). 123 
Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized blood by 124 
density gradient centrifugation on LymphoPrep™ (STEMCELL Technologies™, Vancouver, 125 
Canada) according to Carlsen et al. [21]. The cells were seeded in 8 well Lab-Tek® Chamber 126 
Slide™ Permanox slides (Thermo Scientific, MA, USA) at a density of 5x105 cells/well and 127 
cultured in standard medium containing RPMI 1640 supplemented with 10% heat inactivated 128 
fetal calf serum (FCS), and 0.01 mg/ml gentamicin. Cells were allowed to adhere for 90 129 
minutes at 37 °C and 5% CO2 and non-adherent cells were subsequently removed by washing 130 
the cells twice in PBS.  131 
 132 
2.4. Monocyte infection 133 
C. trachomatis was suspended in RPMI 1640 (Biowest, Nuaillé, France) containing either 134 
10% human autologous serum (NHS) or 10% heat-inactivated human autologous serum 135 
(HIHS) and added immediately to adherent monocytes. S rum was heat-inactivated by 136 
incubating serum for 30 minutes at 56 °C. Infection was carried out for 1, 4 or 24. For 24 137 
hours infection, extracellular bacteria were removed after 4 hours and infection medium was 138 
replaced by standard medium for the remaining incubation period. In some experiments, 139 
medium was supplemented with 10% C3-depleted human serum alone or added 5 µg purified 140 
C3 (Sigma Aldrich) to a final concentration of 20 µg/ml.  141 
For some experiments lipopolysaccharide (LPS) from Escherichia coli (026:B6, Sigma-142 
Aldrich) was used as positive controls at a concentration of 1 µg/ml. 143 
 144 
2.5. Immunofluorescence microscopy 145 
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Immunofluorescence staining was carried out essentially according to Carlsen et al. [21]. 146 
Extracellular bacteria and surface bound CD11b were stained prior to fixation by incubating 147 
cells for 30 minutes at 37 °C with Pab17 (1:200) or anti-CD11b (5 µg/ml) diluted in PBS 148 
containing 0.1% bovine serum albumin (BSA) and 0.05% sodium azide.  Cells were washed 149 
twice in PBS and fixed for 20 minutes in 3.7% formaldehyde at 4 °C. Cells were 150 
permeabilized for 7 minutes in 0.2% Triton-X 100 at room temperature and blocked in 0.1% 151 
BSA for 15 minutes at 37 °C. Primary antibodies were diluted in antibody buffer containing 152 
0.1% BSA in PBS (Mab32.3: 5 µg/ml) and cells were incubated with primary antibody for 30 153 
minutes at 37 °C. Cells were washed three times in antibody buffer and incubated with 154 
secondary antibodies diluted 1:200 in antibody buffer. Cells were washed three times in 155 
antibody buffer and counter-stained with either 2 µM To-Pro-3 Iodide or 2 µM DAPI for 10 156 
minutes at room temperature. Finally, mounting medium was added to each well and slides 157 
were mounted with cover slips.  158 
Cells were visualized and imaged using a Leica SP5 confocal microscope or a Leica DM 159 
5500 B fluorescence microscope. 160 
 161 
2.6. Immunoelectron microscopy 162 
Purified EBs were mixed with 1/10 volume of NHS or HIHS. Five microL purified EB was 163 
added to the surface of carbon-coated glow discharged 400 mesh nickel grids as described 164 
(20). The grids were washed on three drops of PBS (pH 6.5) and blocked on one drop of 1% 165 
ovalbumin (Sigma-Aldrich) in PBS. The grids were thn incubated for 30 min at 37 °C with 166 
1/200 rabbit anti-C3c antibody (Agilent Technologies) diluted in ovalbumin. The grids were 167 
then washed on three drops PBS and incubated for 30 min at 37 °C in goat anti-rabbit 168 
antibodies conjugated with 10 nm colloidal gold (1:25) in ovalbumin. Following this, the 169 
grids were washed on three drops of PBS, incubated on three drops 0.5% cold fish gelatin 170 
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(Sigma-Aldrich) in PBS (10 min each), washed on three drops of PBS, one drop of H2O and 171 
stained with one drop of 0.5% phosphotungstic acid n  blotted dry on filter paper. Electron 172 
microscopy was done at 60 keV on a JEOL 1010 transmission electron microscope (Jeol, 173 
Tokyo, Japan). Images were obtained using a KeenView d gital camera (Olympus Soft 174 
Imaging Solutions GmbH, Münster, Germany).    175 
 176 
 2.7. SDS-PAGE and immunoblotting 177 
Purified EBs from C. trachomatis D and L2 were incubated with an equal volume of either 178 
NHS or HIHS for 30 minutes at 37 °C. EBs were washed twice in PBS with centrifugation at 179 
20000 x g for 15 minutes between each wash. Samples were boiled in RunBlue LDS Sample 180 
Buffer (Expedeon, CA, USA) containing 5% v/v β-mercaptoethanol and proteins were 181 
separated on a 7,5% SDS polyacrylamide gel according to Laemmli (Laemmli 1970). Proteins 182 
were blotted on a nitrocellulose membrane according to Drasbek et al. (Drasbek 2004). The 183 
membrane was blocked in Tris buffered saline (TBS) with 3% gelatin. Polyclonal Rabbit 184 
Anti-Human C3c Complement (Agilent Technologies) (1:1000) was used as primary antibody 185 
and Anti-Rabbit IgG Alkaline Phosphatase (Sigma-Aldrich) (1:20,000) was used as secondary 186 
antibody. Protein bands were developed by adding BCIP/NBT alkaline phosphatase substrate 187 
(Kem-En-Tec Diagnostics, Taastrup, Denmark). 188 
 189 
2.8. Reinfection assay 190 
Monocytes were cultured and infected according to section 2.1 except PBMCs were seeded in 191 
24-well plates at a density of 2x106 cells/well. After 4 and 24 hours, adherent monocytes were 192 
washed thoroughly three times in PBS and detached by scrabing of cells in 2SP buffer (0.2 M 193 
sucrose, 0.02 M phosphate, pH = 7.2). Monocytes were lysed by ultrasonication and lysates 194 
from two wells were pooled and diluted 1:2 in standrd medium (see 2.3) and added to 195 
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confluent McCoy cells. McCoy cells were incubated for 1 hour at 37 °C and 5% CO2 and 196 
subsequently washed three times in PBS and cultured fo  additional 23 hours in standard 197 
medium containing 2 µg/ml cyclohexamide. 198 
Cells were processed for immunofluorescence staining as described in 2.5.  199 
 200 
2.9. Enzyme-linked immunosorbent assay (ELISA) 201 
IL-6 and IL-8 ELISA kits were purchased from ImmunoTools GmbH and the analyses were 202 
performed according to manufacture’s protocol with minor changes. Briefly, MaxiSorp plates 203 
(NUNC) were coated with capture antibody diluted in PBS over night at 4 °C. Excess binding 204 
was blocked with 1% BSA in PBS for one hour at room te perature. Monocyte culture 205 
supernatants were diluted in 0.1% BSA + 0.05% Tween-20 in PBS and added to the wells and 206 
left for incubation for one hour at room temperature. Captured IL-6 and IL-8 were detected 207 
using a biotinylated detector antibody and subsequently streptavidin conjugated to horseradish 208 
peroxidase (HRP). The enzymatic reaction was initiated by adding the HRP substrate TMB-209 
ONE (Kem-En-Tec Diagnostics) and stopped after 30 minutes by adding 1M HCl.     210 
 211 
2.10. Statistics 212 
Statistical differences between two independent groups were calculated using Student’s t-test. 213 
Multiple comparisons were analyzed by One-way ANOVA with Tukey’s multiple 214 
comparison test. All statistical analyses were performed in GraphPad Prism 7 (GraphPad 215 
Software Inc., CA, USA). P-values < 0.05 were considered statistically significant. 216 
 217 
3. Results 218 
3.1. Investigating the role of complement components in C. trachomatis uptake 219 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
10 
 
 
 
We aimed to investigate whether complement components affect the uptake of C. trachomatis 220 
into monocytes. First, dilutions of C. trachomatis D and L2 were titrated to obtain an average 221 
Chlamydia-to-monocyte ratio of 1. Intracellular chlamydiae wre visualized using a 222 
monoclonal antibody against chlamydial MOMP (Fig. 1A). The intracellular localization in 223 
monocytes were confirmed both by membrane staining against CD11b and by differential 224 
staining of intracellular and extracellular bacteria. Monocytes were infected in media 225 
containing either normal autologous serum (NHS) or heat-inactivated autologous serum 226 
(HIHS). Heat-inactivation of serum was done to denature complement factors, abrogating a 227 
functional complement system. Cells were fixed after 1 hour of infection and chlamydial 228 
uptake was quantified by counting the percentage of infected cells.  229 
Fig. 1B shows that the percentage of infected cells wa  statistically significantly higher for 230 
both serovars after 1 hour of infection in NHS samples compared to HIHS samples. Fig. 1B 231 
also shows that there was no difference between uptake efficiency between serovars. These 232 
findings suggest that C. trachomatis D and L2 are taken up by monocytes with the same 233 
efficiency and that complement-competent serum facilit tes rapid uptake of C. trachomatis D 234 
and L2 into human monocytes. 235 
 236 
3.2. Complement deposition on C. trachomatis D and L2 237 
Our observations suggest that complement opsonization of C. trachomatis D and L2 238 
facilitates uptake into monocytes. Monocytes express different receptors recognizing the C3 239 
opsonins, C3b and iC3b, and it was previously demonstrated that these complement proteins 240 
bind to C. trachomatis L2 [15]. We therefore used a polyclonal antibody against C3c to 241 
visualize possible opsonizing complement by immuno-gold electron microscopy, since C3c is 242 
a common component found in both C3b and iC3b. Purified C. trachomatis D and L2 EBs 243 
were incubated with NHS and subsequently stained against C3c and with gold-conjugated 244 
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IgG as secondary antibody [22]. Fig. 2A+E show thatC3 complement fragments were 245 
deposited in patchy areas on the surface of both serovars when incubated in NHS. In contrast, 246 
when chlamydial EBs were incubated with HIHS, only few gold particles were observed on 247 
the EB surface (Fig. 2B, F). No gold was observed on the EB surface when EBs were 248 
incubated with NHS and anti-C3c was omitted (Fig. 2C, G). To quantify complement 249 
deposition, bacteria associated gold particles and gol  particles associated with the 250 
background were enumerated and these numbers were expressed as a ratio. Fig. 2D+H show 251 
that more gold particles are deposited on the bacteri l surface when incubated with NHS 252 
compared to HIHS. Thus, complement factors containing the C3c domain bind to the surface 253 
of C. trachomatis D and L2 in the presence of NHS, but not HIHS, andthis may account for 254 
the observed differences in uptake efficiency.   255 
 256 
3.3. Investigation of Chlamydia-bound C3 257 
By immune-gold electron microscopy we confirmed that complement C3 fragments bind to 258 
the surface of C. trachomatis D and L2 EBs. However, since C3c is a common structu e 259 
found in different C3 fragments we could not elucidate exactly which fragments were bound 260 
to the EBs or if activation of the cleavage cascade had occurred.  261 
We therefore conducted an immunoblot analysis of puri ied chlamydial EBs incubated in 262 
either NHS or HIHS. Western blotting was performed three times using different sera with 263 
similar results and a representative blot is shown in Fig. 3A. Fig. 3A shows that uncleaved α 264 
and β chains of C3 (119 and 74 kDa, respectively) were present on EB after incubation with 265 
either NHS or HIHS, though much stronger when incubated with NHS. Several other C3 266 
protein bands were bound to both C. trachomatis D and L2 when incubated in NHS. The 267 
protein band observed around 45 kDa corresponds to the α’2 fragment of C3 which is only 268 
found in complement iC3b (Fig. 3B).  These findings showed that the complement cascade is 269 
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only activated in NHS leading to production and binding of iC3b to both C. trachomatis D 270 
and L2. In addition to the protein bands just described, two protein bands were present in the 271 
high molecular area (165 and 250 kDa, respectively) in the lanes in which EB were incubated 272 
with NHS (Fig. 3A). These bands represent fragments of either the α’ chain of C3b or the α´1 273 
chain of iC3b covalently linked to unidentified proteins. Both chains contain an exposed 274 
thioester site that allows covalent interactions betwe n C3b/iC3b and target proteins (Fig. 275 
3B).  276 
Thus, iC3b binds to the surface of both C. trachomatis D and L2 and may be involved in 277 
covalent interactions with chlamydial surface proteins. 278 
 279 
3.4. Complement C3 facilitated uptake of C. trachomatis into monocytes 280 
The above results suggest that C3 opsonization of C. trachomatis could explain the 281 
differential uptake efficiency observed using complement-competent serum and heat-282 
inactivated serum, respectively. To elucidate whether C3 in fact facilitates uptake into 283 
monocytes, we investigated the monocyte uptake of C. trachomatis L2 in the presence C3-284 
depleted human serum after one hour of incubation Fg. 4. shows that using C3-depleted 285 
serum reduces the uptake of chlamydia into monocytes compared to bacteria incubated in the 286 
presence of NHS. Adding purified human C3 to the C3-depleted serum restored the monocyte 287 
uptake efficiency, demonstrating that complement C3 facilitates uptake of C. trachomatis into 288 
monocytes.  289 
 290 
3.4. Intracellular fate of C. trachomatis after complement-mediated monocyte ingestion 291 
As early uptake of C. trachomatis in monocytes is facilitated by complement C3 292 
opsonization, we analyzed the fate of C. trachomatis when ingested by monocytes to 293 
elucidate the biological significance of the rapid uptake.  294 
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We have previously observed that both serovar D and L2 etection diminishes over time in 295 
monocytes (data not shown), suggesting that both serovars are eradicated in monocytes. 296 
One previous study demonstrated that C. rachomatis D and L2 can survive intracellularly in 297 
monocytes for up three days post infection [23]. These results conflict with our initial 298 
observations, and we speculated whether the observed diff rences may be due to the 299 
presence/absence of functional complement. To test this, we evaluated the viability and 300 
growth potential of complement-opsonized and non-opsonized C. trachomatis L2 using a 301 
reinfection assay. Monocytes containing C. trachomatis L2 were lysed by ultrasonication and 302 
the lysates were applied to confluent McCoy cells. The viability of ingested bacteria was 303 
evaluated by quantifying the percentage of McCoy cells containing mature inclusions (Fig. 304 
5A, right image). As demonstrated in Fig 5A (table), only few McCoy cells contained mature 305 
inclusions when C. trachomatis was incubated with monocytes for 4 hours. No differences in 306 
chlamydial viability were observed between NHS and HIHS, suggesting that complement-307 
mediated uptake of C. trachomatis does not affect intracellular degradation of C. trachomatis 308 
in monocytes.  When C. trachomatis was incubated within monocytes for 24 hours no mature 309 
inclusions were observed in either condition demonstrating that C. trachomatis is efficiently 310 
killed in monocytes independently of complement.  311 
 312 
3.6. Complement modulation of C. trachomatis induced cytokine production 313 
We showed that complement C3 potentiates the chlamydial uptake, and that uptake leads to 314 
efficient intracellular killing of the bacteria, whic  is one of the primary roles of monocytes 315 
during infection. Another key role of monocytes during infection is to produce and secrete 316 
inflammatory cytokines potentiating anti-microbial immune mechanisms. Thus, to further 317 
extend our understanding of the functional consequences of bacterial opsonization we 318 
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explored if complement affects secretion of IL-6 and IL-8 in monocytes incubated with C.319 
trachomatis.  320 
Monocytes were cultured for 4 hours with C. trachomatis L2 in either NHS or HIHS, LPS or 321 
media alone. After 4 hours of incubation cells were washed and new medium was added and 322 
cells were incubated for further 20 hours. The conditioned monocyte medium was harvested 323 
and the concentration of IL-6 and IL-8 was determined by ELISA.  324 
As shown in Fig. 5B. C. trachomatis induces the secretion of both IL-6 and IL-8 as repo ted  325 
previously [7,24]. Neither IL-6 or IL-8 secretion were significantly affected by the presence 326 
of functional complement since monocytes incubated in NHS and HIHS demonstrates similar 327 
concentrations of the cytokine. However, for both cytokines a small non-significant difference 328 
was observed between NHS and HIHS with a higher concentration in monocytes incubated 329 
with HIHS. Thus, complement opsonization does not affect C. trachomatis induced secretion 330 
of IL-6 and IL-8 in monocytes. 331 
 332 
4. Discussion 333 
We demonstrated that purified EBs of the two serovars, D and L2, of C. trachomatis activated 334 
the complement system leading to deposition of C3 fragments on the chlamydial surface and 335 
that complement C3 facilitates rapid chlamydial uptake into human primary monocytes 336 
leading to bacterial elimination and cytokine production. 337 
Complement activation and complement-mediated phagocytosis of bacterial agents by 338 
monocytes and macrophages have been demonstrated for different intracellular bacteria such 339 
as M. tuberculosis and Listeria monocytogenes [25,26]. Other studies have demonstrated the 340 
ability of C. trachomatis to activate the proteolytic complement cascade leading to activation 341 
of both the C3- and C5-convertase [15,27].  342 
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To our knowledge, we are the first to demonstrate dir ct involvement of complement C3 in 343 
monocyte ingestion of C. trachomatis and that complement C3 is deposited on the surface of 344 
C. trachomatis D EBs. Additionally, using immunoelectron microscopy, we directly 345 
visualized complement deposition on serovar L2 previously reported by Hall et al. [15]. We 346 
found that complement was activated generating iC3b which was bound to the surface of both 347 
serovar D and L2. iC3b is a potent opsonin that has been involved in opsonization and 348 
phagocytosis of other intracellular bacteria such as M. tuberculosis [25].  349 
iC3b is recognized by complement receptor 3 (CR3), a heterodimeric integrin consisting of 350 
CD11b and CD18 that is ubiquitously expressed on the surface of monocytes [28]. CR3 351 
participates in phagocytosis of other intracellular b cteria, such as Mycobacteria spp. and 352 
Peyron et al. [29] showed that CR3 is involved in lipid raft-dependent internalization of M. 353 
kanasii. In line with these findings, it has been demonstrated that the integrity of lipid rafts is 354 
important for host cell entry of several C. trachomatis serovars [9,30]. Additionally, binding 355 
and internalization of Borellia burgdoferi was shown to be dependent on complement C3 and 356 
CD14-dependent recruitment of CR3 to lipid rafts, suggesting that CD14 may also be 357 
involved in the enhanced uptake, since CD14 is widely expressed on monocytes [31,32]. 358 
Thus, it seems likely that the enhanced uptake of C. trachomatis observed in NHS is due to 359 
iC3b-mediated phagocytosis by CR3 engagement. However, iC3b is not exclusively 360 
recognized by CR3. CR1 and CR4 can also bind iC3b leading to iC3b-mediated phagocytosis 361 
[33].  362 
An important parameter to discuss in this context is the involvement of the complement 363 
anaphylatoxins C3a and C5a, which are generated by proteolytic cleavage of C3 and C5 364 
during complement activation. These inflammatory mediators were not investigated in the 365 
current study, but we demonstrate C3 cleavage and, therefore, we know that C3a is generated. 366 
Although some degree of C3b inactivation was observed, it is likely that the complement 367 
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cascade proceeds to C5 cleavage. This was previously shown by Megran and colleagues who 368 
demonstrated that C. trachomatis L2 induced cleavage of C5 to C5a [27]. Both 369 
anaphylatoxins are recognized by G-protein coupled receptors expressed on monocytes. 370 
These mediators could likely contribute to the increased monocytic phagocytosis, since C5aR 371 
antagonists were shown to reduce phagocytosis of heat-killed Staphylococcus aureus in 372 
monocytes [34]. Supporting this observation, it was demonstrated that both C3a and C5a 373 
upregulates CD11b surface expression in neutrophils and monocytes [35]. The contribution of 374 
the anaphylatoxins was not addressed in our study, but literature suggests that anaphylatoxins 375 
likely contribute to the observed effects presented in this study [27,34,35] 376 
 377 
A unique feature of C3 opsonins is their ability to covalently attach to target structures 378 
through a thioester site located in the α’ chain of C3b and in the α’1 chain of iC3b (Fig. 3B). 379 
Our data suggest that iC3b is covalently attached to protein structures on both serovars since 380 
several high molecular protein bands are observed under both denaturing and reducing 381 
conditions. Under reducing conditions iC3b will split into three protein fragments: α’1 (63 382 
kDa), α’2 (39 kDa), and β (75 kDa) [36]. We observe the latter two, but not the α’1 fragment. 383 
The α’1 fragment is likely located in the observed high molecular bands covalently attached 384 
to other proteins. It was previously proposed that C3 fragments interact with MOMP on the 385 
chlamydial surface, but it was not conclusively determined due to antibody cross-reactivity 386 
[15]. We observed anti-C3c reactive protein bands migrating approximately at 165 and 250 387 
kDa, which does not correspond to the summed molecular mass of MOMP and the α’1 388 
fragment (40 kDa + 110 kDa, respectively). The protein bands observed around 250 kDa 389 
suggest that iC3b interacts with high molecular weight surface structures. Potential high 390 
molecular candidates to interact with C3 are the polym rphic membrane proteins, which 391 
ranges in size from 95 kDa to 187 kDa, however this wa  not further investigated. 392 
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We used immunoelectron microscopy to directly visualize protein deposition on the EB 393 
surface. Interestingly, we observed that the C3 fragments were loosely bound to the 394 
chlamydial surface and this observation does not fit with the idea that C3 is covalently linked 395 
to chlamydial outer membrane proteins, however, several chlamydial-complement bindings 396 
may be involved. It has been demonstrated that LPS is loosely bound in the chlamydial outer 397 
membrane and we observed a very similar gold-labelling pattern that could suggest that C3 398 
also interacts with non-protein structures like LPS, which has been demonstrated for other 399 
bacteria previously [22,37]. 400 
The loosely attachment of complement to the bacterial surface may be advantageous to the 401 
bacterium allowing some degree of complement shedding which can reduce the rapid 402 
recognition and ingestion by phagocytes. Thus, comple ent binding to C. trachomatis EBs 403 
may involve interactions with both protein structures and LPS on the bacterial surface. 404 
 405 
We showed that uptake of C. trachomatis was accompanied by rapid inactivation and 406 
elimination of the bacteria inside monocytes. In our experiments, no viable chlamydiae were 407 
recovered after 24 hours inside monocytes even though chlamydia could still be detected by 408 
immunofluorescence staining against MOMP at this time (data not shown). This demonstrates 409 
the limitation of antibodies as a detection tool when questions regarding bacterial viability is 410 
addressed. Under these circumstances, it is important to include functional assays or include 411 
analyses of bacterial metabolites that can highlight important differences in bacterial viability. 412 
There is some ambiguity related to the fate of C. trachomatis in monocytes and macrophages. 413 
In murine macrophages C. trachomatis L2 is rapidly directed to destructive intracellular 414 
compartments including both lysosomes and autophagosomes [38]. However, a study using 415 
primary human monocytes showed that C. rachomatis can remain viable and infectious after 416 
48 hours in monocytes [23]. In addition, the authors f und no reduction in the number of 417 
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infected cells over a 72-hour period which conflicts with our observations. This discrepancy 418 
may be explained by the infection method, since Datta et al. [23] used centrifugation for 419 
monocyte infection. It was previously demonstrated that centrifugation of C. psittaci on 420 
McCoy cells reduced the bacterial association with cell lysosomes compared to static 421 
infection [39]. Thus, using centrifugation instead of static infection the normal endo-422 
lysosomal pathway may be omitted leading to increased chlamydial survival and growth. This 423 
remains to be demonstrated in monocytes, but it is well-known that the mechanisms and 424 
receptors involved in the uptake process influence the subsequent intracellular fate of the 425 
ingested organism in monocytes and macrophages. Beside altered intracellular trafficking 426 
induced by complement receptor signaling also comple ent anaphylatoxins may affect the 427 
intracellular fate of C. trachomatis in monocytes. Anaphylatoxins can modulate the 428 
production of reactive oxygen species (ROS) in monocytes, which have been proposed to be 429 
important for intracellular degradation of C. trachomatis [35,40]. Mollnes et al. showed that 430 
an antibody directed against C5a was able to inhibit E.coli-induced ROS production in both 431 
monocytes and neutrophils [35]. Therefore, it is important to consider possible effects of 432 
anaphylatoxins when looking at intracellular survival of C. trachomatis in monocyte cultures 433 
supplemented with fresh serum. These observations, t gether with our results, emphasizes the 434 
need to carefully revise the methods used for cell-chlamydia culture/infection used in many in 435 
vitro studies on host-chlamydial interactions, since method parameters such as centrifugation 436 
and culture supplements have important implications f r the observed biological effects. 437 
  438 
In this study, we did not observe any statistically significant effect of complement on 439 
chlamydia-induced cytokine secretion. Several studies, however, suggest that monocyte 440 
cytokine secretion can be triggered and/or potentiated by the presence of complement. Both 441 
C3a and C5a was demonstrated to induce IL-8 secretion in human neutrophils and that 442 
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specific antibodies against these anaphylatoxins reduc d PAMP-induced cytokine secretion 443 
(Vecchiarelli 1998). Similar effects were later observed in monocytes when Cheng et al. 444 
showed that complement C5a potentiates Candida albicans-induced cytokine production in 445 
human PBMCs [41]. Asgari and colleagues [42] further demonstrated that C5a directly 446 
induces IL-6 secretion and that C3a receptor ligation potentiates LPS-induced IL-1β 447 
production in human primary monocytes. Thus, both anaphylatoxins may influence the 448 
cytokine profiles observed in this study.  449 
 450 
Both macrophages and complement are present in the genital mucosal lining, and during 451 
infection-induced inflammation additional circulating monocytes are recruited [6,43,44]. 452 
Thus, complement activation and complement-directed phagocytosis by monocytes may 453 
provide an important innate mechanism to restrict chlamydial infection. This is further 454 
supported by in vivo studies using knock-out mice inf ction models. C3-/- mice displayed 455 
decreased survival following intranasal infection with different chlamydial species compared 456 
to wild-type mice and this reduced survival was not attributed to differences in antibody titers 457 
[44,45]. Thus, our findings could provide a mechanistic explanation for the observed 458 
differences between C3-/- and wild-type mice, but generally it is difficult to translate 459 
complement-mediated effector functions demonstrated in vitro to the complex in vivo 460 
environment. This was highlighted by a study by Yang et al. who demonstrated that 461 
Chlamydia-induced pathology were C5-dependent, but occurred independently of C3 [46]. 462 
This observation conflicts with the normal paradigm of complement activation where C5 463 
functions downstream of C3 activation and cleavage. Thus, several in vivo factors can 464 
modulate complement functions, and these were not addressed in our “clean” in vitro system. 465 
These factors could include other cell-types expressing complement receptors or soluble 466 
factors, such as coagulation factors neither of which were included in our experimental setup. 467 
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Thus, during initial infection, before adaptive immunity is developed, complement 468 
opsonization with C3 and subsequent monocytic phagocytosis may be a key process for 469 
controlling bacterial dissemination until adaptive mmunity is developed.  470 
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Figure legends 641 
Fig. 1. Immunofluorescence assay of C. trachomatis uptake into human monocytes. Primary 642 
human monocytes were incubated with C. trachomatis D and L2 in media supplemented with 643 
either normal autologous human serum (NHS) or heat-inactivated autologous human serum 644 
(HIHS) for 1 hour. Cells were fixed, immunestained using a chlamydial MOMP antibody and 645 
the number of infected cells was quantified. A-D) Confocal microscopy of monocytes fixed 646 
after 1 hour post infection and stained against MOMP (green). E) Intracellular location of EBs 647 
(green) in monocytes was confirmed by CD11b surface staining (red). F) Extracellular and 648 
intracellular bacteria were distinguished by successive staining of extracellular and 649 
intracellular bacteria (red and green, respectively).  G) Percentage of infected cells at 1 hour  650 
post infection. Data were from three independent experiments with duplicate samples in each. 651 
All data are presented as means ± SEM. * indicates P < 0.05. Scale bars indicate 10 µm. 652 
 653 
Fig. 2. Transmission electron microscopy of immunostained purified C. trachomatis serovar 654 
D and L2 EBs. Primary antibody: rabbit anti C3c and secondary antibody: goat anti rabbit IgG 655 
conjugated with 10 nm colloidal gold. A) Serovar D EB incubated with NHS subsequently 656 
stained for C3c. B) Serovar D EB incubated with HIHS and thereafter stained for C3c. C) 657 
Serovar D EB incubated with NHS and thereafter secondary colloidal gold conjugated 658 
antibody. D) Serovar L2 EB incubated with NHS and thereafter stained for C3c. E) Serovar 659 
L2 EB incubated with HIHS and thereafter stained for C3c. F) Serovar L2 EB incubated with 660 
NHS and thereafter secondary colloidal gold conjugated antibody. G+H) Chlamydia-661 
associated gold particles were counted from three chlamydial EBs from two independent 662 
experiments (6 cells for each condition). Gold particles per area was estimated for the bacteria 663 
and the background, respectively, and a ratio of these numbers was used as quantitative 664 
measure of gold particle deposition. The data are represented as means ± SEM. Scale bar 665 
indicates 200 nm. 666 
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 667 
Fig. 3. Immunoblot analysis of complement C3 deposition on C. trachomatis EBs. C. 668 
trachomatis D and L2 were incubated in either NHS and HIHS, washed and proteins were 669 
separated under reduced conditions on a 7.5% SDS gel, transferred to a nitrocellulose 670 
membrane and stained with anti-C3c. A) Different fragments of complement C3 are deposited 671 
on chlamydial EBs when incubated in NHS. The blot shows C3 (119 kDa and 74 kDa), iC3b 672 
(74 kDa and 45 kDa) depositions, and in addition bads of higher molecular size (165 and 673 
250 kDa) were seen after incubation with NHS. B) Diagram showing the consecutive 674 
cleavage of C3 with theoretical molecular sizes of the cleavage products. 675 
 676 
Fig. 4. Effect of complement C3 on chlamydial uptake into mnocytes. Monocytes were 677 
incubated with C. trachomatis L2 for 1 hour in the presence of either NHS, HIHS, C3-678 
depleted serum (∆C3) or C3-depleted serum + purified human C3 (∆C3+C3). The cells were 679 
fixed after 1 hour, stained against chlamydial MOMP, and the percentage of infected cells 680 
were quantified. Statistically significantly more clls were infected in presence of NHS 681 
compared to C3-depleted serum. Adding C3 to C3-deplet d serum causes a statistical 682 
significant increase in percentage of infected cells. Data were from four biologically 683 
independent experiments with duplicate samples in each. All data are presented as means ± 684 
SEM. * indicates P < 0.05. n.s.: non-significant difference. 685 
 686 
Fig. 5. Functional consequences of complement-mediated uptake of C. trachomatis into 687 
monocytes. A) Intracellular survival of C. trachomatis L2 in monocytes. Monocytes were 688 
incubated with C. trachomatis L2 for 4 or 24 hours in media containing either NHS or HIHS 689 
and subsequently lysed by ultrasonication. Monocyte lysates were added to confluent McCoy 690 
cells for one hour and McCoy cells were incubated for additional 23 hours. Chlamydial 691 
inclusions were identified by immunofluorescence staining against MOMP. Left image: 692 
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McCoy cells with EB that had not developed to an inclusion (arrowhead). Right image: 693 
McCoy cell with an inclusion (green) from monocytes incubated in HIHS. Table: Mean 694 
percentage (± SEM) of McCoy cells containing mature inclusions quantified from duplicate 695 
samples from three biological independent experiments. Scalebars indicate 10 µm.  696 
B) IL-6 and IL-8 concentrations in media from monocytes cultured with C. trachomatis L2. 697 
Monocytes were incubated with C. trachomatis L2 for 4 hours in media supplemented with 698 
either NHS or HIHS. After 4 hours, extracellular bacteria were removed and the monocytes 699 
were incubated for further 20 hours. The culture supernatants were harvested and used for 700 
ELISA. Standard medium and standard medium supplemented with 1 µg/ml LPS were used 701 
as negative and positive controls, respectively. No statistically significant differences were 702 
observed between and NHS and HIHS groups. Each condition was analyzed in triplicates and 703 
three biologically independent experiments were performed. Data are presented as means ± 704 
SEM. 705 
 706 
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